GlassScriptPhysician profile
Vineeth K Sukrithan
NPI 1659788800
$28,169.68
in general payments reported to CMS, 2019-2025
8 companies · $7,528 in 2025
The $7,528 reported for 2025 was more than what 78% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2022: $9,281 · 2023: $3,636 · 2024: $7,597 · 2025: $7,528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $7,528 · Consulting Fee: $2,960 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,750 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,750 · Travel and Lodging: $1,998 · Food and Beverage: $775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $7,527.50 |
| Consulting Fee | $2,960.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,750.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,750.00 |
| Travel and Lodging | $1,998.47 |
| Food and Beverage | $774.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $10,903.55 | 2023-2025 | Cabometyx |
| Lantheus Medical Imaging, INC. | $4,777.50 | 2025 | |
| Ge Healthcare | $4,611.00 | 2022 | |
| Progenics Pharmaceuticals, INC. | $4,590.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,960.00 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $199.80 | 2022-2024 | Onivyde |
| Genentech USA, INC. | $127.83 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vineeth Sukrithan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.